Related Experiment Video
Updated: Jun 10, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Interleukin 2 in cancer therapy.
1Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
Interleukin-2 (IL-2) immunotherapy offers long-term control for advanced cancers like melanoma and renal cell carcinoma. Future cancer treatments may combine IL-2 with novel therapies to enhance efficacy and manage toxicity.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Interleukin-2 (IL-2) is an established immunotherapy for advanced cancers.
- IL-2 has shown long-term disease control in metastatic renal cell carcinoma and malignant melanoma.
- Emerging cancer therapies include kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines.
Purpose of the Study:
- To review the established activity and toxicity of IL-2 in advanced malignancies.
- To explore the potential of combining IL-2 with novel cancer therapeutic strategies.
- To speculate on the future applications of IL-2 in cancer treatment.
Main Methods:
- Literature review of IL-2 efficacy and toxicity in cancer.
- Analysis of current trends in cancer immunotherapy development.
- Discussion of potential combination strategies involving IL-2.
Main Results:
- IL-2 demonstrates significant activity in specific advanced malignancies.
- Novel therapies are being developed for cancer treatment.
- Combining IL-2 with other agents is a growing area of interest.
Conclusions:
- IL-2 remains a valuable agent in managing advanced cancers.
- Future cancer immunotherapy may involve synergistic combinations with IL-2.
- Careful consideration of toxicity is crucial when integrating IL-2 into novel treatment regimens.
More Related Videos
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...